Our Pipeline

Diverse pipeline of innate cell engagers designed to activate innate immunity

A number of clinical and preclinical programs are in development based on the ROCK® platform and our tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy.

Innate Cell Engagers

AFM13

Disease Target CD30
Peripheral T cell lymphoma (AFM13-202)
Phase 2
Transformed mycosis fungoides (AFM13-202)
Phase 2
CD30-positive T cell lymphoma (AFM13-102)
Phase 2
HL (post BV and post anti-PD-1) (AFM13-201)
Phase 2

AFM13 + adoptive NK cells

Disease Target CD30
CD30-positive lymphoma (AFM13-104)
Phase 1

AFM13 + anti-PD-1

Disease Target CD30
Hodgkin lymphoma (post BV) (AFM13-103)
Phase 1

AFM24

Disease Target EGFR
Solid tumors (AFM24-101)
Phase 1

AFM24 + adoptive NK cells

Disease Target EGFR
Multiple solid tumors (AFM24-103)
IND Cleared

AFM24 + anti-PD-L1

Disease Target EGFR
Multiple solid tumors (AFM24-102)
IND not required

AFM28

Disease Target Undisclosed
Undisclosed
Pre-IND

AFM32

Disease Target Undisclosed
Solid tumors
Pre-IND

Genentech

Disease Target Undisclosed
Multiple Programs
Pre-IND

ICE® + NK cell combination: co-vialed, cryopreserved, off-the-shelf

Disease Target Undisclosed
Undisclosed
Pre-IND
Affimed programs
Partnered programs

Selected posters & publications:

  • Wingert et al., mAbs 2021; 13(1):1950264: Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors
  • Kerbauy et al., Clin Cancer Res 2021: Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies
  • Bartlett et al., Blood 2020: A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Please see: Blood 2020; 136: 2401–2409.
  • Pahl et al., AACR 2021: AFM24 is a novel, highly potent, tetravalent bispecific EGFR/CD16A-targeting Innate Cell Engager (ICE®) designed for the treatment of EGFR-positive malignancies View poster
  • Reusch et al., AACR 2020: AFM24, a bispecific EGFR/CD16A Innate Cell Engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies View poster
  • Ellwanger et al., mAbs 2019: Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity. Please see: mAbs 2019; 11:899-918.
  • Sawas et al., 15-ICML 2019: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202) View poster
  • Oral Presentation: Ansell et al., ICML 2019: Investigating safety and preliminary efficacy of AFM13 plus Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure View poster
  • Bartlett et al., ASH 2018: A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data View poster
  • Marin et al., ASH 2018: The CD30/CD16A Bispecific Innate Immune Cell Engager AFM13 Elicits Heterogeneous Single-cell NK Cell Responses and Effectively Triggers Memory Like (ML) NK Cells View poster
  • Wingert et al., ASH 2018: CD16A-Specific Tetravalent Bispecific Immuno-Engagers Potently Induce Antibody-Dependent Cellular Phagocytosis (ADCP) by Macrophages View poster
  • Kluge et al., AACR 2018: Preclinical Characterization of the Bispecific EGFR/CD16A Innate Immune Cell Engager AFM24 for the Treatment of EGFR-Expressing Solid Tumors View poster

See all Publications & Posters